SBC Medical Group Holdings Incorporated (SBC) Stock Price & Analysis
SBC Medical Group Holdings Incorporated (SBC) closed at USD 5.3 on Thursday, October 15, 2026, up 1.34% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 5.23; the Oct 15, 2026 session ranged USD 5.11–5.3 on volume of 139,685 shares. Market capitalization is $545.09M, with a 52-week range of USD 2.78–5.61 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/SBC.md
Key facts (SBC)
- Last four reported quarters (through Jun 30, 2026): revenue $175M, net income $49.0M (28.0% margin), free cash flow $61.8M (SEC filings).
- Valuation: P/E 11.1x (avg 15.3x at the last 3 fiscal year-ends), EV/EBITDA 5.9x, net cash $147M.
- Analysts: Buy (mean 1.67 on a 1–5 scale) (3 analysts), mean target USD 8.75 (range 7–11).
- Total return with dividends: 1Y +27.1% vs S&P 500 +18.1%; 5Y -47.1% vs S&P 500 +85.1%.
- Next earnings: 2026-11-13, EPS estimate USD 0.12, revenue estimate $48.9M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (SBC)
| USD | FY2024 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|
| Revenue | $194M | $205M | $174M | $175M |
| Gross profit | $137M | $156M | $127M | — |
| Operating income | $70.7M | $70.3M | $67.5M | $65.4M |
| Net income | $39.4M | $46.6M | $51.0M | $49.0M |
| EPS (diluted) | $0.42 | $0.48 | $0.50 | — |
| Free cash flow | $42.1M | $18.0M | $23.3M | $61.8M |
| Gross margin | 70.9% | 76.0% | 73.3% | — |
| Operating margin | 36.5% | 34.2% | 38.9% | 37.3% |
| Net margin | 20.3% | 22.7% | 29.4% | 28.0% |
| Revenue growth | — | +6.1% | -15.5% | — |
| Cash + short-term investments | $103M | $125M | $164M | — |
| Total debt | — | $6.9M | $43.1M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (SBC)
P/E 11.1x · P/S 3.1x · EV/EBITDA 5.9x · EV/Sales 2.3x · P/FCF 8.8x · P/B 2.1x · FCF yield 11.33% · Earnings yield 8.99% · Net cash $147M · EV $398M
P/E at fiscal year-ends: Dec 2025 8.7x, Dec 2024 11.5x, Dec 2023 25.8x.
Analysts (SBC)
Consensus Buy (mean 1.67 on a 1–5 scale), 3 analysts; mean target USD 8.75 (low 7, high 11).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-13 | BTIG | Reiterated | Buy | $8 |
Total return (dividends reinvested) (SBC)
| 1Y (from 2025-10-16) | 5Y (from 2022-09-26) | |
|---|---|---|
| Total return | +27.1% | -47.1% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +27.2% | -14.5% |
| Volatility (annualized) | 55.8% | 70.1% |
| Max drawdown | -41.7% (Feb 2026→May 2026) | -81.0% (May 2024→Jun 2026) |
Key Statistics (as of October 16, 2026 at 05:21 UTC)
| Price | USD 5.3 |
|---|---|
| Change | ▲ 1.34% (up) |
| Previous Close | USD 5.23 |
| Open | USD 5.23 |
| Day Range | USD 5.11 – 5.3 |
| 52-Week Range | USD 2.78 – 5.61 |
| Volume | 139,685 shares |
| Market Cap | $545.09M |
| Exchange | NGM |
Technical Analysis (SBC)
Nexqual's technical model rates SBC "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 16, 2026 at 05:21 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 64.87 (neutral) |
| vs SMA50 | Above (USD 4.42) |
| MACD | 0.26 (positive) |
Analyst Ratings (SBC)
Wall Street analysts rate SBC "Buy" based on 3 analysts, with a mean price target of USD 8.75 (range USD 7–11), per Nexqual as of October 16, 2026 at 05:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 8.75 |
| High Target | USD 11 |
| Low Target | USD 7 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (SBC)
| Next Earnings Date | 2026-11-13 |
|---|---|
| EPS Estimate | USD 0.12 |
| Revenue Estimate | $48.89M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.1 vs est 0.12 ▼ miss |
| 2026-03-31 | USD 0.11 vs est 0.1 ▲ beat |
| 2025-12-31 | USD 0.14 vs est 0.12 ▲ beat |
| 2025-09-30 | USD 0.12 vs est 0.11 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financials & Fundamentals (SBC)
| Total Revenue | $175.17M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +13.40% |
| Gross Margin | +71.85% |
| Operating Margin | +38.55% |
| Profit Margin | +27.99% |
| ROE | +18.91% |
| Debt / Equity | 0.17 |
| Current Ratio | 3.31 |
| Total Cash | $184.62M |
| Total Debt | $48.23M |
| Free Cash Flow (fiscal year ended Dec 2025, SEC 10-K) | $23.27M (13.4% of revenue) |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financial Health Score (SBC)
Nexqual rates SBC Medical Group Holdings Incorporated's overall financial health "Solid" across five dimensions, as of October 16, 2026 at 05:21 UTC.
| Growth | Critical — Revenue -15% YoY (annual), sharp decline |
|---|---|
| Profitability | Strong — Gross margin 72%, operating 39% |
| Balance Sheet | Strong — $185M cash vs $48M debt, net cash position |
| Cash Flow | Solid — FCF $23M (FY ended Dec 2025, 10-K), 13% margin |
| Efficiency | Solid — ROE 19%, ROA 11.3% |
Ownership (SBC)
| Insider Ownership | +81.53% |
|---|---|
| Institutional Ownership | +4.45% |
| Shares Outstanding | 102.85M |
| Float | 18.10M |
| Short % of Float | +4.29% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Leadership (SBC)
SBC Medical Group Holdings Incorporated is led by Yoshiyuki Aikawa (age 54), Chairman & CEO, per Nexqual as of October 16, 2026 at 05:21 UTC.
| Chairman & CEO | Yoshiyuki Aikawa (age 54) |
|---|---|
| COO, CFO & Director | Yuya Yoshida (age 45) |
| Chief Strategy Officer | Miki Yamazaki (age 39) |
| Chief Marketing Officer | Shinya Inoue |
| COO of SBC Medical Group Co., Ltd. (Japan) | Hiroyuki Miya |
Major Backers & Investors (SBC)
Notable institutional backers of SBC Medical Group Holdings Incorporated include Lumbard & Kellner, LLC, Fidelity, Citadel, according to Nexqual as of October 16, 2026 at 05:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Lumbard & Kellner, LLC | 1.68% |
| Fidelity | 0.31% |
| Citadel | 0.14% |
| Hillsdale Investment Management Inc. | 0.12% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 1.49% |
| Vanguard Group | 0.5% |
| Geode Capital | 0.42% |
| Northern Trust | 0.13% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ROMA | Roma Green Finance Limited | USD 8.34 | ▼ 1.42% |
| PPHC | Public Policy Holding Company, | USD 10.59 | ▲ 0.09% |
| CRAI | CRA International,Inc. | USD 177.35 | ▼ 0.92% |
| ICFI | ICF International, Inc. | USD 88.77 | ▲ 1.52% |
| HURN | Huron Consulting Group Inc. | USD 175.47 | ▼ 0.49% |
| FCN | FTI Consulting, Inc. | USD 146.24 | ▲ 6.06% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt